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Abstract
Integrins are a family of transmembrane adhesion proteins that mediate cell attach-
ment to extracellular matrix or to another cell. The T cell LFA-1 integrin and its
interaction with its predominant ligand, ICAM-1, is known to regulate antigen-driven
differentiation of naive T cells into effector T cells, a process that is fundamental
to adaptive immunity. The activation of LFA-1 on effector and naive T cells is still
unclear and requires further investigation for a more detailed understanding. In this
work we quantitatively study primary T cells (both naive and effector) and their
interaction with ICAM-1 using atomic force microscopy (AFM). Measurements show
that adhesion of the effector T cell is in general at least one order of magnitude
higher than that of the naive T cells. OKT3 treatment has a profound impact on T
cell–ICAM-1 interaction, resulting in at least a 2-fold increase in both detachment
force and work. Our conclusions corroborate past research that shows that there is a
higher expression of LFA-1 on effector T cells than naive T cells and that LFA-1 on
effector T cells is predominantly in the high affinity state. Our results also possibly
indicate that a mixed population of high and low affinity LFA-1 is present on naive
cells. Furthermore, given the response to OKT3 treatment, it is likely that it induces
populations of LFA-1 to change from low affinity to high affinity on both effector
and naive T cells. Taken together, our studies reveal in more detail the regulation
and conformational states of high affinity LFA-1 on T cells which is critical to T cell
activation. Additionally, we use AFM to look at the interaction between neuropilin-2
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(NRP-2), a type I transmembrane glycoprotein, which is expressed on cancer cells
and show that it interacts with α5 integrin on endothelial cells. Most importantly,
our studies reveal that the interaction mediates cancer cell vascular extravasation and
promotes metastasis. This research further supports the highly promising route of
preventing cancer metastasis by therapeutically blocking NRP-2 and thereby greatly
improving the prognoses of cancer patients.
2
Part I
Integrin mediated cell adhesion in
primary T lymphocytes
3
Chapter 1
Introduction
Integrins are obligate heterodimeric transmembrane adhesion molecules that contain
both a distinct α- and β-subunit (of which 18 α-subunits and 8 β-subunits have been
found) and are broadly expressed on a large variety of cells [1, 2, 3]. They function
both as adhesion molecules and as receptors for outside-in signalling, a process
that involves sending into the cell information about the mechanical and chemical
properties of the extracellular milieu. Integrin is unique in that it usually remains
in an inactive form on the surface of the cell until it is activated by the action of
inside-out signaling in which stimulating signals from other receptors are received.
The activation of integrin involves a dramatic conformation change from a closed,
bent shape to an extended, open one [4, 5]. There are a few distinct conformations
that integrin is capable of and each has its own ligand binding affinity based on
conformational [6, 7, 8, 9, 10, 11] and structural [12, 13, 14, 15] studies.
The main integrin in T cells/lymphocytes is lymphocyte function-associated
antigen-1 (LFA-1; CD11a/CD18, αLβ2) which is part of the β2 subclass of integrins
[16, 17]. LFA-1 is known to be involved in two T cell activities: cell arrest and
subsequent migration on surfaces expressing the main LFA-1 ligand, intercellular
adhesion molecule-1 (ICAM-1; CD54), and formation of immunological synapses
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by interacting with antigen-presenting cells (APCs). ICAM-1, mentioned earlier,
is a cell surface glycoprotein that is the predominant ligand of LFA-1 and their
interaction controls certain key lymphocyte roles such as cell migration, antigen
presentation and lymphocyte extravasation [18, 19, 20, 21, 22, 23].
LFA-1 is expressed on the leukocyte surface in an inactive state. In order to
bind to ICAM-1 with strong affinity, cellular activation is required; in particular
certain avidity (receptor clustering) and affinity (molecule conformational change)
enhancements are required [24, 25, 26]. In humans, modulation of LFA-1 activation
performs a key role during inflammatory and immune responses [27, 28, 29, 30].
The ICAM-1 binding site of LFA-1 has been localized to the metal ion-dependent
adhesion site (MIDAS) on the inserted-domain (I-domain) of the LFA-1 αL subunit
[31]. The I-domain changes conformation upon activation from the low affinity (closed
conformation) state to the high affinity (extended conformation) state, resulting
in increased affinity for ligand binding [32, 33]. In T lymphocytes, a cascade of
intracellular progressions that increase the affinity of LFA-1 for ICAM-1 occurs when
the T cell receptors (TCRs) are engaged [34].
After T cell development, matured naive T cells, T lymphocytes that have not
yet encountered the antigen they are programmed to respond to, leave the thymus
and spread throughout the body. Fundamental to adaptive immunity is the direction
of developmental cues from cells of the innate immune system for antigen-driven
differentiation of naive T cells into effector T cells. It is known that this process
is regulated by LFA-1 on the T cell and its interaction with ICAM on the APC
through the immunological synapse [35, 36, 37]. Effector T cell LFA-1 is important
in effector functions and migration and it has been shown that in effector T cells
LFA-1 is highly expressed. Conversely, it has been also been shown that in naive
cells there is a lower LFA-1 expression [38]. Recent research provides evidence that
in primary effector T cells the I-domain of LFA-1 changes to the high affinity state
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and that high affinity LFA-1 is crucial in T cell activation [39].
The activation of LFA-1 on the effector and naive T cells is still unclear and
requires further investigation for a more detailed understanding. Herein, we study
whole primary T lymphocytes (both naive and effector T cells) and their interaction
with ICAM-1 in a more quantitative method utilizing atomic force microscopy (AFM)
[40, 41].
6
Chapter 2
Materials and methods
2.1 T cells
Primary effector and naive T cells were kindly provided by the Ma Group at the
MD Anderson Cancer Center. The cells were maintained at 37 ºC in RPMI 1640
medium supplemented with 10% serum prior to AFM measurements.
2.2 T cell–ICAM-1 adhesion measured by atomic
force microscopy
The experimental apparatus used to measure cell adhesion is schematically illustrated
in Figure 2.1. ICAM-1 was coated on standard 35mm tissue culture dishes while
a single T cell was coupled to the end of the cantilever via poly-L-lysine-mediated
linkages. In order to prepare the poly-L-lysine-functionalized cantilevers, they
were soaked in acetone for 5min, irradiated by UV for 30min, incubated in 100mM
NaHCO3 (pH 8.6) for 20min at room temperature, washed three times with phosphate
buffered saline (PBS, 10mM PO3−4 , 150mM NaCL, pH 7.3) and incubated in poly-
L-lysine (PLL, 0.1mg/mL in PBS; Sigma P4832) overnight at 4 ºC in a humidified
7
Figure 2.1: AFM schematic for measuring contact forces between T cells
and ICAM-1. Shown in this schematic are the major components of a custom-
built AFM coupled to an inverted optical microscope, which allows for viewing
of the cells. A single T cell (designated in orange in the figure) is attached to a
poly-L-lysine-functionalized cantilever and is lowered onto the portion of the dish
coated with ICAM-1 (designated in blue) by the action of the piezoelectric translator.
A laser (~635 nm) is reflected off the cantilever into the photodiode. The voltage
difference between segments A and B of the photodiode gives the amount of cantilever
deflection.
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(a) (b)
Figure 2.2: Cycle of AFM measurement and retraction trace. (a) Schematic
representation of a typical cycle of the AFM measurement: 1) approach of the T cell
to the ICAM-1 coated spot, 2) contact between the T cell and the ICAM-1 coated
spot, 3) retraction of the T cell, and 4) separation of the T cell from the ICAM-1
coated spot. Arrows indicate the direction of cantilever movement. (b) Typical force
spectrum trace after a 5 s contact and with a compression force limit set at 500 pN.
Grey and black curves are approach and retract traces, respectively. Two-headed
arrow indicates the magnitude of detachment force on the retract (black) trace.
chamber.
Measurements of T cell–ICAM-1 interaction were conducted in RPMI 1640
medium at 25 °C. With the aid of an optical magnification system situated below the
AFM, the tip of the poly-L-lysine-functionalized cantilever was positioned above a T
cell in the medium and gently lowered to the surface of the dish for approximately
1 s to attach the cell to the cantilever. At the onset of the measurements the T cell,
coupled to the AFM cantilever, was positioned directly above the portion of the dish
coated with ICAM-1.
The relative position of the interacting T cell and ICAM-1 surface was controlled
via expansion or contraction of the piezoelectric translator. The force acting between
the surface and cell was derived from the deflection of the AFM cantilever, which
was monitored by reflecting a focused laser beam off the back of the cantilever
into a 2-segment photodiode. Cantilevers were individually calibrated by thermal
fluctuation analysis [42] and had spring constants of approximately 0.015N/m.
As illustrated in Figure 2.2a, AFM measurements of the interaction between an
individual T cell and ICAM-1 involves a series of four steps. First, the cantilever
with an attached T cell is lowered onto the ICAM-1 coated spot. At a certain point
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contact is made, allowing for ICAM-1–receptor interaction to take place. A trigger
signal is set so that the piezoelectric translator will stop its downward motion and
prevent crushing of the cell or damaging the cantilever. The cantilever is subsequently
retracted via the contraction of the piezoelectric translator, pulling the T cell and
ICAM-1 apart until complete separation is achieved. During this process, the AFM
continuously monitors the force of the cantilever in order to report on the interaction
between the T cell and ICAM-1.
A typical AFM force-displacement record of AFM single cell adhesion assay is
presented in Figure 2.2b. In this figure, the y-axis plots the cell–surface interaction
force as a function of the relative distance between the base of the cantilever and
surface (i. e. the ICAM-1). At the beginning of the force measurement, when the
attached cell (T cell) is several microns above the surface, there is no strain on the
cantilever. At this position, which is marked by the lower dashed line, the force
is zero. Expansion of the piezoelectric translator lowers the attached cell onto the
surface. Following cell–surface contact, further expansion of the translator presses
the attached cell against the spot on the dish coated with ICAM-1. The compression
force felt by the cells is determined from the upward deflection of the cantilever. For
the measurements of T cell–ICAM-1 adhesion, the predefined limit of the compression
force was set at 500 pN. Once this force value is reached the expansion of the translator
ceases. This compression force is held for a predefined cell–surface contact time
before the translator contracts to initiate cell–surface separation. We used a contact
duration of 5 s. Upon retraction of the cantilever, molecular linkages established
between the cell and surface pull the cantilever downward. The cell detachment
process typically involves a series of rupture events. Each of these rupture events
resulted in a rapid jump in force and may correspond to the unbinding of one or
more adhesive ligand–receptor bonds.
To quantify the adhesion between the T cells and ICAM-1, we measure the
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“detachment force” and “detachment work.” As indicated by the double-headed arrow
in Figure 2.2b, the detachment force is the maximal pulling force applied by the
cantilever during the detachment process. The detachment work is derived from
integrating the adhesive force over the distance traveled by the cantilever up to the
point of the last bond rupture. Both parameters have been used to quantitate single
cell adhesion in the literature.
2.3 Statistical analysis
ANOVA or t-test was used for statistical analysis, with p < 0.05 considered statisti-
cally significant. Standard error mean is indicated in the data.
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Chapter 3
Results
Figure 3.1 shows the detachment force and work of T cells bound to the ICAM-1
coated surface. In general, adhesion of the effector T cell is at least one order of
magnitude higher than that of the naive T cell. OKT3 treatment, a mAb which
leads to T cell action [43], has a profound impact on T cell–ICAM-1 interaction,
resulting in at least a 2-fold increase in both detachment force and work. MHM24,
a mAb for the I-domain of human LFA-1, was used for a negative control and its
addition significantly reduced adhesion, suggesting that the measurements being
made are primarily of LFA-1–ICAM-1 interactions.
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Figure 3.1: Detachment force and work between T cells and ICAM-1. (a)
Average detachment forces between T cell and ICAM-1 coated surfaces. (b) Average
detachment work between T cell and ICAM-1 coated surfaces. A 5 s contact time was
used. Error bars are standard error mean from several sets of ~100 measurements.
The error bar is standard error with n ≥ 3 in each case. **p < 0.01 and ***p < 0.001
between the indicated groups.
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Chapter 4
Discussion
Our research quantitatively investigated LFA-1 expression on both primary effector
and primary naive T cells. Adhesion to ICAM-1 is much greater in the effector T
cells than naive T cells and it is likely that there exists a large population of high
affinity LFA-1 on effector T cells. Based on the results it is possible that a large
population of LFA-1 on naive T cells is in the low affinity state or a mixture of low
and high affinity states. The OKT3 treatment induced significant enhancement of
detachment force and work in naive cells which suggests that a population of low
affinity LFA-1 changes to a high affinity state with the treatment. The increased
adhesion in effector cells after OKT3 treatment also suggests that extra adhesion
results from further activation of an inactive population of LFA-1 and/or the induced
clustering of LFA-1 on the cell surface. Another question worth pondering and
investigation is whether there is rebinding during the pulling of multiple bonds.
Furthermore, to fully understand the molecular mechanism of LFA-1 mediated T
cell adhesion more research utilizing molecular dynamic simulations and specific
monoclonal antibodies and/or site-directed mutagenesis is necessary.
Overall, our results confirmed and elaborated in greater detail past studies of LFA-
1 expression and confirmation on naive and effector T cells. Further investigation,
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particularly in single molecule conditions will further reveal greater details of LFA-1
affinity state in various conditions and is currently in progress.
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Part II
Neuropilin-2 promotes
extravasation and metastasis by
interacting with endothelial α5
integrin
16
Chapter 5
Introduction
Metastasis, the spread of tumor cells from the primary neoplasm to a non-adjacent
organ, is the leading cause of death in cancer patients. The spread of the cancer cells
occurs through multistep processes that are sequential and interrelated. In brief,
it involves cancer cells from the primary tumor acquiring the ability pass through
the walls of the blood and/or lymphatic vessels, intravasting into the blood stream,
traveling through and extravasting the circulation, and subsequently colonizing a
non-adjacent organ [44, 45]. Up to now, limited details on the molecular mechanisms
that regulate the extravasation process and re-entry of the circulating cancer cells
into distal tissues have been seen in the literature. As 90% of mortality from solid
tumors is a result of metastasis [45], a greater comprehension of how this mechanism
functions which will aid in developing effective treatments to halt and treat cancer
metastasis which will lead to a pronounced improvement in prognoses of cancer
patients.
Recently, there has been mounting evidence that implicates neuropilins (NRPs)
as playing a role in extravasation and metastasis of tumor cells. NRPs are type I
transmembrane glycoproteins which include neuropilin-1 (NRP-1) and neuropilin-2
(NRP-2). The two neuropilins were initially identified as multi-functional non-kinase
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receptors for ligands of the class 3 semaphorin, vascular endothelial growth factor
and other growth factors [46, 47, 48, 49, 50, 51, 52, 53, 54, 55]. Both aforementioned
neuropilins have parallels and differences in their functions and share a 45% homology
in their protein sequences. NRP-2 is seen to be less developmentally crucial, as
homozygous NRP-2 mutant mice are still viable with only slight defects [56, 57, 58].
In contrast, NRP-1 homozygous knockout mice suffer significant vascular and neural
issues which lead to mortality [59]. Due to the more benign effects resulting from
a lack of NRP-2, less is currently known about the biological attributes of NRP-2
than NRP-1.
NRP-2 is highly expressed on the surface of certain varieties of tumor cells, such as
those of colorectal carcinoma [60], endocrine pancreatic tumors [61], and pancreatic
adenocarcinoma [62]. The research suggests that NRP-2 expression is correlated in
some form to cancer metastasis [63, 60, 64, 65]. In breast cancer [66] and osteosarcoma
[67], a poor prognosis is associated with NRP-2 expression. Lymph node metastasis
in papillary thyroid carcinoma [64] and breast cancer [66] has also been shown to be
associated with NRP-2 expression. Additionally, endothelial cells of lymphatic vessels
in tumor tissue show expression of NRP-2. It has been shown that administering
blocking antibody to target NRP-2 on lymphatic endothelial cancer cells hinders
tumor lymphogenous metastasis as it inhibits tumor lymphangiogenesis [63]. It
is still unclear what molecular mechanisms with which NRP-2 influences tumor
metastasis. However, regulation of CXCR4 [66] and survival signaling [62, 60, 68]
has been shown to be correlated with NRP-2.
The following work was part of a collaborative effort with the Mukhopadhyay
Group at the Mayo Clinic which resulted in a paper which was recently accepted for
publication [69]. NRP-2 expression in renal cell carcinoma (RCC) and pancreatic can-
cer models was studied and together with our collaborator’s data, cancer metastasis
was shown to be promoted by NRP-2. This occurs uniquely through an interaction
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between α5 integrin on the surface of endothelial cells and NRP-2 expressed on
tumor cells, where NRP-2 functions as an adhesion molecule. The studies expose
a potential mechanism for tumor cell vascular adhesion and extravasation which is
mediated by NRP-2 and ultimately uncover the clinically important role of NRP-2
in promoting cancer metastasis.
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Chapter 6
Materials and methods
6.1 Cell culture
Human RCC cell line 786-O (ATCC) was maintained in DMEM medium (10% FBS,
1% penicillin/streptomycin). Likewise, pancreatic cancer cell line AsPC-1 (ATCC)
was maintained in RPMI-1640 (10% FBS). Variants of these cell lines, in particular
those with knocked down or overexpressed NRP-2 expression were prepared and
provided by our collaborators [69]. All experiments used 5mM EDTA in PBS to
detach the cancer model cells from the culture dish as NRP-2 was found to be a trypsin
sensitive membrane protein. Human umbilical vein endothelial cells (HUVECs; Lonza,
San Diego, CA) were cultured in endothelial basal medium supplemented with EGM-
MV Bullet kit (5% fetal bovine serum (FBS), 12 μg/ml bovine brain extract, 1 μg/ml
hydrocortisone, and 1 μg/ml GA-1000). In the experiments, HUVECs of passages 3–5
were used. Bovine collagen type I (BD Biosciences) was used to coat the dishes used
in the HUVEC culture. α5 integrin antibody (Clone: 5H10-27(MFR5); Biolegend)
was used for blocking.
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Figure 6.1: AFM schematic for measuring contact forces between 787-
O/AsPC-1 cells and HUVECs. Shown in this schematic are the major com-
ponents of a custom-built AFM coupled to an inverted optical microscope, which
allows for viewing of the cells. A single 786-O cell (designated in orange in the
figure) is attached to a Con A-functionalized cantilever. This in turn is lowered
onto the plated HUVECs (designated in yellow) by the action of the piezoelectric
translator. A laser (~635 nm) is reflected off the cantilever into the photodiode. The
voltage difference between segments A and B of the photodiode gives the amount of
cantilever deflection.
6.2 786-O/AsPC-1 cell–HUVEC adhesion measured
by Atomic force microscopy
Atomic force microscopy (AFM) is a technique used to measure the mechanical
contact force between cells [40, 41] and is utilized in this experiment to study the role
NRP-2 plays in mediating interaction between cancer cells and endothelial cells. The
experimental apparatus used to measure cell adhesion is schematically illustrated
in Figure 6.1. In methods previously described [70, 71], HUVECs were plated on
standard 35mm tissue culture dishes while a single 786-O/AsCP-1 cell was coupled
to the end of the AFM cantilever (MLCT, Bruker Nano, Camarillo, CA). Atomic
force microscopy was used to control the relative position of the interacting cells via
expansion or contraction of the piezoelectric translator. The force acting between
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the cells was derived from the deflection of the AFM cantilever, which was monitored
by reflecting a focused laser beam off the back of the cantilever into a 2-segment
photodiode. Cantilevers were individually calibrated using the equipartition theorem
[42] and had spring constants ranging from 0.015N/m to 0.025N/m.
The AFM force measurements were carried out by a custom-built AFM with the
individual cancer cells attached to the tip of an AFM cantilever via Concanavalin A
(Con A)-mediated linkages. In order to prepare the Con A-functionalized cantilevers,
they were soaked in acetone for 5min, irradiated by UV for 30min, incubated
in biotinamidocaproyl-labeled bovine serum albumin (biotin-BSA, 0.5mg/mL in
100mM NaHCO3, pH 8.6; Sigma, St. Louis, MO) overnight at 37 °C, rinsed three
times with phosphate-buffered saline (PBS, 10mM PO3−4 , 150mM NaCl, pH 7.3)
and incubated in streptavidin (0.5mg/mL in PBS; Pierce, Rockford, IL) for 30min
at room temperature. Unbound streptavidin was removed by rinsing the cantilevers
with PBS and the cantilevers were incubated in biotinylated Con A (0.5mg/mL in
PBS; Sigma) for 15min at room temperature and rinsed with PBS. With the aid
of an optical magnification system situated below the AFM, the tip of the Con A-
functionalized cantilever was positioned above the center of a cell and gently lowered
onto the cell for approximately 1 s to attach the cell to the cantilever. Measurements
of cancer cell–endothelial cell interaction were conducted in EBM medium at 25 °C.
At the onset of the measurements the cancer cell, coupled to the AFM cantilever,
was positioned directly above either the center of an isolated HUVEC, or a HUVEC–
HUVEC cell junction in a Petri dish seeded with HUVECs to approximately 50%
confluency.
As illustrated in Figure 6.2a, AFM measurement of the interaction between an
individual 786-O cell and a HUVEC involves a series of four steps. The cantilever
with an attached 786-O/AsPC-1 cell is first lowered onto a HUVEC. A trigger
signal is set so that the piezoelectric translator will stop its downward motion and
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(a) (b)
Figure 6.2: Cycle of AFM measurement and retraction trace. (a) Schematic
representation of a typical cycle of the AFM measurement: 1) approach of the cancer
cell to the HUVEC, 2) contact between the cancer cell and the HUVEC, 3) retraction
of the cancer cell, and 4) separation of the cancer cell from the HUVEC. Arrows
indicate the direction of cantilever movement. (b) Typical force spectrum retraction
trace for a cancer cell bound to a HUVEC cell body. Measurements were acquired
with a compression force of 500 pN, 1 s contact, and a cantilever retraction speed
of 3.5 μm/s. Shaded area in the trace is the “detachment work.” Arrows point to
rupture events, i. e. breakage of adhesive bond(s). Dashed line indicates zero forces.
prevent crushing of the cell or damaging the cantilever. Following a 1 s contact
at a compression force of 500 pN, the cantilever is subsequently retracted with a
speed of 3.5 μm/s, pulling the 786-O/AsPC-1 cell–HUVEC pair apart until complete
separation of the two cells is achieved. During this process, the AFM continuously
monitors the force of the cantilever in order to report on the interaction between the
786-O/AsPC-1 cell and the HUVEC. A typical AFM retraction trace is presented
in Figure 6.2b. Upon retraction of the cantilever, molecular linkages established
between the cells pull the cantilever downward. The cell detachment process typically
involves a series of rupture events, as indicated by arrows, and may correspond to the
detachment of one or more adhesive ligand–receptor bonds. To quantify the adhesion
between 786-O/AsPC-1 cells and HUVECs, we measured the “detachment work,”
which is derived from integrating the adhesive force over the distance traveled by
the cantilever up to the point of the last bond rupture (shaded area in Figure 6.2b)
[72, 73]. In the experiments the detachment work was determined for 786-O/AsPC-1
cells that had normal NRP-2 expression (control), NRP-2 knocked down, and NRP-
2 overexpressed. These measurements were also performed with anti-α5 integrin
23
antibody added at a concentration of 10 μg/mL and preincubated for 30min before
commencing measurements.
6.3 Statistical analysis
ANOVA or t-test was used for statistical analysis, with p < 0.05 considered statisti-
cally significant. Standard error mean is indicated in the data.
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Chapter 7
Results
7.1 Quantification of cancer cell–endothelial cell
interaction mediated by NRP-2
Figure 7.1a shows the detachment work of HUVEC bound to 786-O control, NRP-2
knockdown or overexpressing 786-O cells. In general, HUVEC cell–cell junctions
are about 40% to 60% more adhesive to the 786-O cell. Compared to NRP-2
knockdown 786-O cells, an approximately 200% increase (p < 0.05) of detachment
work was detected on NRP-2 overexpressed 786-O cells. Anti-α5 integrin antibody
has a profound impact on 786-O cell–HUVEC adhesion. In both HUVEC bodies and
cell junctions, incubation of the 786-O cells with the antibody completely diminished
the enhanced adhesion induced by NRP-2 overexpression. In addition, α5 integrin
blockages also inhibited adhesion between 786-O control cells and HUVEC cell
junctions. Figure 7.1b shows that in AsPC-1 pancreatic cancer cells, knockdown of
NRP-2 significantly decreased detachment work of HUVEC junctions. Furthermore,
AsPC-1 cell–HUVEC adhesion in bodies and junctions was abrogated by anti-α5
integrin antibody. These findings suggest that NRP-2 is an adhesion molecule which
promotes the adhesion between cancer cells and endothelial cells and that α5 integrin
25
(a) (b)
Figure 7.1: Detachment work between cancer cells and HUVEC. (a) Adhe-
sion strength between a single pair of 786-O cell and HUVEC (upper panel: HUVEC
cell body; lower panel: HUVEC cell junctions) measured by the detachment work.
(b) Adhesion strength between a single pair of AsPC-1 cell and HUVEC (upper
panel: HUVEC cell body; lower panel: HUVEC cell junctions) measured by detach-
ment work. The error bar is standard error with n > 5 in each case. *p < 0.05
and **p < 0.01 between the indicated groups. CTRL, control 786-O; KD, NRP-2
knockdown; OE, NRP-2 overexpression.
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is a trans-binding partner of NRP-2.
7.2 Results of collaborators
Our collaborators performed a variety of other approaches to studying NRP-2 which
were further complemented and supported by the results of our experiments. They
used an in vivo RCC xenograft tumor model (nude mice with subcutaneously injected
tumor cells, 786-O among them) to show that NRP-2 depletion decreased metastasis
but did not influence primary tumor growth. To further extend these results the
collaborators examined clear cell RCC (ccRCC) patient samples utilizing a tissue
microarray (TMA) and found that NRP-2 expression was higher in patients with
more a more advanced tumor stage. Using another TMA they also found that NRP-2
was notably higher in metastatic carcinoma than primary tumors. This suggests
that NRP-2 is involved particularly in cancer metastasis.
An important step in metastasis is extravasation of the cancer cells from the
circulation to colonize a distant site from the original organ. To study NRP-2’s role
in this step the collaborators used an in vivo cancer metastasis extravasation model.
Zebrafish embryos were injected with 786-O cells and they later found that cells with
NRP-2 overexpressed were actively extravasating while the control cells exhibited
none of this behavior. These results single out that a role in cancer metastasis that
NRP-2 plays a part in is extravasation of cancer cells. Following this another study
was done using an in vitro cell adhesion assay which further expounded upon the
gathered data by showing that the interaction between cancer cells and endothelial
cells is mediated by surface expression of NRP-2.
To bridge the above experiments to other types of tumor cells, the extremely
metastatic pancreatic cancer cell line, AsPC-1 was similarly studied. in vitro NRP-2
depletion was found to reduce the ability of AsPC-1 to adhere to an endothelial
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monolayer. In the same zebrafish extravastion model, knockdown of NRP-2 in AsPC-
1 showed similar results as before, with an observation of reduced extravasation
of cancer cells. In a similar mouse xenograft model, NRP-2 knockdown noticeably
reduced cancer metastasis. In addition, a prospectively acquired cohort of patients
with pancreatic cancer showed that high NRP-2 expression correlated with poor
patient survival.
Finally, our collaborators hypothesized that during cancer metastasis, an integrin
expressed on the surface of endothelial cells interacts with NRP-2. They were able
to identify α5 integrin as one that interacts with NRP-2 and that HUVECs have a
much higher expression of it then 786-O cells.
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Chapter 8
Discussion
The results that we obtained confirmed and quantified the data that our collaborators
collected. Taken together, it reveals a mechanism in which NRP-2 on a variety of
tumor cells promotes cancer metastasis by mediating the interaction with α5 integrin
on endothelial cells, particularly during the stage of metastasis in which the tumor
cell adheres to the endothelium and extravasates from the circulation to colonize
a distant organ. Other recent research [64, 66, 74] in addition to ours point to
high expression of NRP-2 being correlated with cancer metastasis. Therapeutically
targeting NRP-2 has already been shown to reduce metastasis in some cases in an
in vivo model [63]. Our research uncovers the previously unknown mechanism of
NRP-2 action and the players involved which aids in developing therapeutics to
block NRP-2. This is a highly promising method of preventing cancer metastasis
and greatly improving the prognoses of cancer patients.
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Chapter 9
Concluding remarks
In this work we quantified, using a highly sensitive method, the adhesive strength
of T cells and cancer cells on a substrate and interacting cells, respectively. This
technique is not limited to the chosen systems and can potentially be used to study
a wide range of cell–cell and cell–substrate interactions in various disease-oriented
settings. Our characterization of the T cell–ICAM-1 interaction is far from complete.
A more thorough investigation under single molecule conditions will be needed to
identify the affinity state of LFA-1 under various conditions. We hypothesize that on
naive T cells, most LFA-1 molecules are in an inactive state. Upon OKT3 activation,
some populations of LFA-1 will be induced to high affinity. In effector cells, the
enhanced adhesion compared to naive cells suggests a significant population of LFA-1
is maintained in the high affinity state. Since OKT3 treatment further increased
adhesion in effector cells, the extra adhesion may stem from further activation of
the inactive population of LFA-1 and/or the induced clustering of LFA-1 on the cell
surface. Another open question is the possibility of rebinding during the pulling of
multiple bonds. Although AFM can reveal the dissociation kinetics of cell adhesion
bonds, the association kinetics might be relevant in some cases such as after OKT3
treatment. Moreover, while AFM measurements reveal the force required to pull T
30
cells from the substrate, complementary studies using molecular dynamic simulations
and specific monoclonal antibodies and/or site-directed mutagenesis will be necessary
to fully address the molecular mechanism of LFA-1 mediated T cell adhesion.
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